Big Pharma’s Monopoly On Ozempic Threatens Access To Diabetes Drug In Communities Of Color

Black Americans suffer from obesity at disproportionate rates, but the popular weight-loss drug Ozempic isn’t available in many inner-city neighborhoods. An obscure industry — compounding pharmacies — have found business serving black residents that Big Pharma ignores. The number of people living with diabetes worldwide is on pace to more than double in the next three decades, according to a recent study published in The Lancent. This increase will bring the total of worldwide diabetic patients to a staggering 1.3 billion by 2025, making diabetes one of the top 10 leading causes of death and disability in the world. On December 5th of 2017, a little-known drug called Ozempic hit the market to help millions of people suffering with diabetes. Ozempic was created to lower blood sugar by stimulating the pancreas to produce more insulin and has shown continual success in patients with lowering their A1-C. The introduction of medications such as Ozempic and Wegovy has changed the game for millions of people worldwide who have been struggling with diabetes. The medication was once a weekly auto injector that would allow patients to maintain their sugar levels and create a healthier way of life. One of its known side effects,...